+240.8%
TWLO vs MRNA
+34.8%
+206.0%
-45.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.6% | +5.4% | -7.0% | -1.7% |
| 7D | -2.4% | -1.1% | -1.3% | -2.4% |
| 30D | -7.8% | +126.1% | -133.9% | -10.3% |
| 3M | +10.0% | +190.0% | -180.0% | +3.3% |
| 6M | +79.5% | +157.2% | -77.8% | +70.4% |
| YTD | +59.8% | +388.2% | -328.4% | +38.8% |
| 1Y | +121.7% | +467.0% | -345.4% | +87.2% |
| 3Y | +240.8% | +36.1% | +204.7% | +203.4% |
| All | +240.8% | +34.8% | +206.0% | +203.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling